Kornimate/medical-research-clean huggingface dataset:
multifunctional nutrition tube in dysphagia for nasopharyngeal carcinoma

Conditions: Dysphagia

Summary: this is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for npc. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received ioe while the control group received ngt for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (qol) after treatment as well as adverse events are compared.

palliation to delayed dysphagia after radiotherapy for nasopharyngeal carcinoma (npc) continues to be a challenge. although nasogastric tube feeding (ngt) has been adopted widely, the weaknesses have yet to be improved by another enteral nutrition support mode. this study aims to observe the clinical efficacy of intermittent oro-esophageal tube feeding (ioe) in the treatment of delayed dysphagia after radiotherapy for (npc). this is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for npc. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received ioe while the control group received ngt for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (qol) after treatment as well as adverse events are compared.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years. * with the history of npc and radiation therapy. * with dysphagia occurred at least three years after radiotherapy (confirmed by videofluoroscopic swallowing study), in need of and feasible for enteral nutrition support. * conscious and with stable vital signs; * willing to participate and sign the written informed consent form either personally or by a family member. exclusion criteria: * presence of other diseases that might cause dysphagia. * with distant metastasis of tumors, or complicated with severe systemic disorders or malignancies. * concurrent participation in other treatments that could interfere with the trial. * inability to cooperate with treatment due to aphasia, mental health issues, etc. * received tube feeding for enteral nutrition support within the past three years.
oral disintegrating ondansetron tablet to reduce vomiting from gastroenteritis in a pediatric emergency department

Conditions: Gastroenteritis; Vomiting; Diarrhea; Dehydration

Summary: the objectives of the study were to determine whether ondansetron treatment would reduce: * the amount of vomiting in the emergency department; * the need for intravenous rehydration; and * the need for hospitalization.

background: vomiting may limit the success of oral rehydration in children with gastroenteritis and dehydration. limited data suggest that while oral ondansetron may reduce vomiting from gastroenteritis, emergency department revisits may increase. methods: the investigators conducted a prospective, double-blind randomized trial at a pediatric emergency department in 214 dehydrated children, aged 6 months to 10 years with gastroenteritis and mild to moderate dehydration as assessed by a dehydration score. they were randomly assigned to receive treatment with an ondansetron oral disintegrating tablet or placebo. oral rehydration was administered according to a standard protocol. the primary outcome was the proportion of children who vomited during oral rehydration therapy. the secondary outcomes were the mean number of episodes of vomiting, and the proportion of children treated with intravenous rehydration or hospitalized.

Eligibility criteria:
inclusion criteria: * acute gastroenteritis * non-bilious and non-bloody vomiting within 4 hours of triage * diarrhea * mild to moderate dehydration exclusion criteria: * weight less than 8 kilograms * severe dehydration * underlying disease which might affect the assessment of hydration status (e.g., chronic renal failure, hypoalbuminemia, congestive heart failure, on diuretics) * history of abdominal surgery * hypersensitivity to the drug or any components in its formulation
pharmacogenomics of glp1 receptor agonists

Conditions: Type 2 Diabetes

Summary: healthy volunteers were recruited from the old order amish population in lancaster county, pennsylvania. after providing informed consent, research participants were screened for eligibility. the clinical trial was designed as a randomized crossover study in which participants underwent two frequently sampled intravenous glucose tolerance tests - one after receiving a subcutaneous injection of saline and one after receiving a subcutaneous injection of rapid-acting exenatide (byetta). the study sought to determine whether genetic variants are associated with the magnitude of the effect of exenatide. if an association were identified, this would help physicians to predict whether an individual patient is likely to have a large response to the class of diabetes drugs to which exenatide belongs (glp1 receptor agonists).

healthy volunteers were recruited from the old order amish population in lancaster county, pennsylvania. after providing informed consent, research participants were screened for eligibility. the clinical trial was designed as a randomized crossover study in which participants underwent two frequently sampled intravenous glucose tolerance tests (fsigt) - one after receiving a subcutaneous injection of saline and one after receiving a subcutaneous injection of rapid-acting exenatide (byetta). based on data obtained from the fsigt, participants' response to exenatide was assessed -- specifically, the effect of exenatide to enhance insulin secretion and accelerate metabolism of glucose. the study sought to determine whether genetic variants are associated with the magnitude of the effect of exenatide. if an association were identified, this would help physicians to predict whether an individual patient is likely to have a large response to the class of diabetes drugs to which exenatide belongs (glp1 receptor agonists).

Eligibility criteria:
inclusion criteria: * member of the old order amish community in lancaster county, pennsylvania * bmi: 18-40 kg/sq.m. exclusion criteria: * known allergy to exenatide * history of diabetes, random glucose \>200 mg/dl, or hba1c \> 6.5% * significant debilitating chronic cardiac, hepatic, pulmonary, or renal disease or other diseases that the investigator judges will make interpretation of the results difficult or increase the risk of participation * seizure disorder * pregnant by self-report or known pregnancy within 3 months of the start of study * currently breast feeding or breast feeding within 3 months of the start of the study * estimated glomerular filtration rate \<60 ml/min/1.73m2 * hematocrit \<35% * liver function tests greater than 2 times the upper limit of normal * abnormal tsh * history of pancreatitis or pancreatic cancer. personal or family history of medullary carcinoma of the thyroid.

Keywords: glp1 insulin glucose exenatide glp1 receptor agonist insulin secretion glucagon receptor gip receptor
bioequivalence study of carbidopa/levodopa/entacapone combination vs. carbidopa/levodopa combination plus entacapone under fasting conditions in healthy volunteers

Conditions: Healthy

Summary: the purpose of this study is to assess the safety and bioequivalence of a single oral dose of carbidopa+levodopa+entacapone combination versus a single oral dose of carbidopa+levodopa combination plus a single oral dose of entacapone under fasting conditions in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects age 18 to 55 years of age included, and in good health * at screening, and baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed after the subject has rested for at least five (5) minutes, and again when required after three (3) minutes in the standing position. vital signs should be within the normal ranges * body mass index (bmi) within the range of 18 to 27 and weigh at least 50 kg * female subjects must have undergone hysterectomy, or must be postmenopausal. exclusion criteria: * history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease * history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin * receiving monoamine oxidase (mao) inhibitors within 28 days prior to the first dose * a positive hepatitis b surface antigen (hbsag) or hepatitis c test result * history of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). a known hypersensitivity to the study drug or drugs similar to the study drug. * significant illness within two weeks prior to dosing * subjects who, through completion of the study, would have donated in excess of: 500 ml of blood in 14 days; 1500 ml of blood in 180 days; 2500 ml of blood in 1 year. * history of immunodeficiency diseases, including a positive hiv (elisa and western blot) test result. * history of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations. * women of child bearing potential ( wocbp) * history or presence of glaucoma or any suspicious undiagnosed skin lesions other protocol-defined inclusion/exclusion criteria may apply

Keywords: bioequivalence bioavailability carbidopa levodopa entacapone fasting condition healthy volunteers study
prospective trial of oral vancomycin therapy vs. placebo for prevention of cdi

Conditions: CDI

Summary: the purpose of this research study is to determine in patients receiving intravenous (iv) antibiotic(s), if giving oral vancomycin therapy will prevent c. difficile-associated infection (commonly called cdi). oral vancomycin is an antibiotic that is commonly used to treat cdi. the investigators want to study if using this drug can prevent the development of cdi while you are in the hospital receiving iv antibiotics. the key risk factors for developing cdi are age and iv antibiotic therapy. cdi is an infection in your colon caused by an organism called clostridium difficile (or c. diff for short) that causes diarrhea. up to 12% of hospital-acquired infections have been reported to be cdi. it can lead to longer hospital stays and more costs associated with the hospital stay.


Eligibility criteria:
inclusion criteria: * 1. older patients (\> 65 years of age), hospitalized for \> 48 hours and treated with parenteral antimicrobial therapy for \> 48 hours at chi creighton university medical center-bergan mercy will be eligible for enrollment. exclusion criteria: 1. patients diagnosed with cdi within the first 72 hours of hospitalization and/or diagnosed with cdi within the past 3 months 2. patients diagnosed with gastrointestinal infection other than cdi 3. patients who have received a solid-organ transplant in the past 12 months 4. females who are pregnant or immediately post-partum 5. patients admitted to the hospital with an opportunistic infection secondary to hiv-1 and cd4 cell count of \< 200 cell/mm3 6. patients receiving cancer chemotherapy or immune modulator drugs (i.e. checkpoint inhibitors; pd-1/pd-l1 inhibitors; biologic dmards) as examples 7. patients being treated with ≥ 28 days of intravenous (iv) antimicrobials (complex s. aureus bacteremia, osteomyelitis, endocarditis)
messaging strategies to increase peer education on covid-19 vaccination and climate change

Conditions: Vaccine Hesitancy; Climate Change

Summary: the primary objective of this protocol is to develop and evaluate peer communication interventions to encourage peer education around covid-19 vaccination and climate change.

investigators will use a rct peer education intervention to address climate change-related behaviors as a control condition for the vaccination intervention. both issues represent serious public health priorities and are sufficiently unrelated in order to act as control conditions for each other. as a control topic, investigators will address climate change communication. this parallel topic was selected because it is (1) reasonably unrelated to the covid-19 condition, (2) has clear individual-level behaviors that can be targeted for intervention, (3) has diversity in public attitudes like covid-19 vaccines,18 (4) has parallels in covid-19 in terms of polarization and discrediting of scientific research, (5) represents a significant threat to population health, and (6) has significant racial and ethnic disparities paralleling those of covid-19. investigators will recruit a second sample of up to 800 eligible participants who will be asked to complete an intervention session, where they will receive training on how to talk to members of their social network about either covid-19 vaccination or climate change. the two intervention conditions will differ based on topic (vaccination/climate change) but the intervention components will be comparable. during the intervention, participants will watch a series of videos that teach key communication skills for having conversation about the assigned topic. additional videos will provide training in how to use social media as a communication platform to share information in case participants are unfamiliar. participants will then complete practice activities where they will construct hypothetical conversations and react to/critique example conversations to practice implementing the communication skills. upon completing the intervention, participants will be asked to try to talk to others in their social network about the topic area they were assigned to. two to four weeks after the intervention, participants who completed the intervention will be asked to complete a follow-up survey to assess whether participants had conversations with others in their social networks, if they used social media/text/e-mail to share accurate information, and to understand the outcome of the conversations (i.e. did they result in behavior change).

Eligibility criteria:
inclusion criteria: * english-speaking * english-reading * reside in the united states * over 18 years of age * have passed prolific's data quality checks on their previously submitted work * have heard of covid-19 and the covid-19 vaccine exclusion criteria: * do not provide informed consent.
chest mobility, strength, physical activity and quality of life in parkinson's patients with post-covid-19

Conditions: COVID-19 Respiratory Infection; Parkinson Disease

Summary: to comparative pain intensity, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in parkinson's patients with post-covid-19 and without post-covid-19 was aimed in current study. knowledge in the literature regarding this topic is still obscure.

acute worsening and long-term sequelae of motor and non-motor symptoms have also been described in parkinson's patients during and after sars-cov-2 infection, which is also known as prolonged covid. the effects of covid-19 on pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in parkinson's patients are still unclear today. for this reason, in this study, it was aimed to comparatively investigate pain, chest mobility, cough strength, muscle strength, physical activity levels and quality of life in parkinson's patients with covid-19 and without covid-19 and to show the relationships between these outcome measures.

Eligibility criteria:
inclusion criteria for parkinson's patients with post-covid-19; * being diagnosed with covid-19 at least 12 weeks ago and recovered, * being over 18 years old, * volunteering to participate in the research, * being diagnosed with parkinson's disease * comorbid conditions (such as hypertension, diabetes) are under control * being able to perceive assessments (standardized mini mental test score of 24 and above) * having the ability to ambulate and walk independently * being in stage 1 - 4 according to the modified hoehn-yahr scale inclusion criteria for parkinson's patients without post-covid-19; * not being diagnosed or suspected of covid-19 * being over 18 years old, * volunteering to participate in the research, * being diagnosed with parkinson's disease * having comorbid conditions (such as hypertension, diabetes) which are under control * being able to perceive assessments (standardized mini mental test score of 24 and above) * having the ability to ambulate and walk independently * being in stage 1 - 4 according to the modified hoehn-yahr scale exclusion criteria for parkinson's patients with and without post-covid-19; * sudden drug or dose change during the study period * a history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made. * having had myocardial infarction and pulmonary embolism in the last 30 days, * having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than parkinson's disease * having severe vision loss or vestibular dysfunction * patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on ecg, with a history of shortness of breath and/or palpitation

Keywords: pain chest mobility cough muscle strength physical activity quality of life
impact of a computerized guidelines on the management of hypertension and diabetes

Conditions: Diabetes Mellitus; Hypertension

Summary: the purpose is to determine wether an electronic decision support system based on national guidelines is effective to improve the follow-up and the treatment of two conditions: hypertension and diabetes, in primary care practices.

existing computer-based ordering systems for physicians provide drug-centred checks but offer little assistance for optimizing the overall patient-centred treatment strategy. the asti project aims : 1. to design a guideline-based decision support system for diabetic and/or hypertensive patients, to help general practitioners : 1. to carry out procedures (clinical and biological tests) according to guidelines (the recommended procedure at the recommended moment), and to get a synthetic view of all the elements they need to follow-up the patient 2. to avoid prescription errors and to improve compliance with therapeutic guidelines. the " critic mode " operates as a background process and corrects the physician's prescription on the basis of automatically triggered elementary rules that account for isolated guideline recommendations. the " guided mode " directs the physician to the best treatment by browsing a comprehensive guideline knowledge base represented as a decision tree. 2. to measure the impact of asti when it is implemented with an electronic medical record system. we adopt a randomized design, with the practice as the unit of randomization.

Eligibility criteria:
inclusion criteria: * hypertension * mellitus diabetes * follow-up by gp's

Keywords: guideline based decision support system, hypertension, diabetes
effect of ketoconazole on biliary excretion of azd0837

Conditions: Healthy

Summary: this is an explorative study and the scientific question to be investigated is if the biliary excretion of azd0837 and its metabolites ar-h069927xx and ar-h067637xx are affected by co-administration with ketoconazole


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive exclusion criteria: * significant illness, trauma or surgical procedures. * clinically significant laboratory abnormalities. * clinically significant medical history

Keywords: pharmacokinetics
pk & tolerability of cnv1014802 in young and elderly healthy volunteers

Conditions: Trigeminal Neuralgia

Summary: a randomized, double-blind, placebo controlled, two period crossover study to investigate the pharmacokinetics, tolerability and cognitive effects of 8 days dosing of cnv1014802 in healthy young versus elderly male and female subjects. treatment periods will be separated by 13 days. the primary outcome measures are pharmacokinetics (pk) and tolerability.

this study was previously posted by convergence pharmaceuticals, ltd., which has been acquired by biogen.

Eligibility criteria:
key inclusion criteria: * healthy male and female over 18 years using acceptable methods of contraception key exclusion criteria: * positive pre-study hiv, hepatitis b surface antigen or positive hepatitis c antibody * history or evidence of alcohol or drug abuse * pregnant or lactating females * participation in a clinical trial within 3 months or the current study or exposure to more than four new chemical entities within 12 months. * use of prohibited concomitant medication * history or presence of any clinically significant abnormality in vital signs / ecg / laboratory tests, or have any medical or psychiatric condition, which, in the opinion of the investigator may interfere with the study procedures or compromise subject safety. * relevant history of a suicide attempt or suicidal behavior note: other protocol defined inclusion/exclusion criteria may apply